|
1
|
Baska F, Bozó É, Szeleczky Z, Szántó G, Vukics K, Szakács Z, Domány-Kovács K, Kurkó D, Vass E, Thán M, Vastag M, Temesvári K, Lévai S, Halász AS, Szondiné Kordás K, Román V, Greiner I, Bata I. Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist. J Med Chem 2024; 67:643-673. [PMID: 38165765 DOI: 10.1021/acs.jmedchem.3c01868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2024]
Abstract
The V1a receptor is a major contributor in mediating the social and emotional effects of arginine-vasopressin (AVP); therefore it represents a promising target in the treatment of several neuropsychiatric conditions. The aim of this research was to design and synthesize novel and selective V1a antagonists with improved in vitro and in vivo profiles. Through optimization and detailed SAR studies, we developed low nanomolar antagonists, and further characterizations led to the discovery of the clinical candidate compound 43 (RGH-122). The CNS activity of the compound was determined in a 3-chamber social preference test of autism in which RGH-122 successfully enhanced social preference with the lowest effective dose of 1.5 mg/kg.
Collapse
Affiliation(s)
- Ferenc Baska
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | - Éva Bozó
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | | | - Gábor Szántó
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | | | | | | | - Dalma Kurkó
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | - Elemér Vass
- Institute of Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/A, Budapest H-1117, Hungary
| | - Márta Thán
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | - Mónika Vastag
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | | | - Sándor Lévai
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | | | | | - Viktor Román
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| | | | - Imre Bata
- Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary
| |
Collapse
|
|
2
|
Ackley W, Dahl NK, Park M. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. ADVANCES IN KIDNEY DISEASE AND HEALTH 2023; 30:228-235. [PMID: 37088525 DOI: 10.1053/j.akdh.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 02/09/2023] [Accepted: 02/14/2023] [Indexed: 04/25/2023]
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder and the fourth leading cause of end-stage kidney disease. ADPKD encompasses a wide range of morbidity in addition to chronic kidney disease and end-stage kidney disease, and its pathogenesis remains incompletely understood. Progress in the management of this condition includes the 2018 FDA approval of tolvaptan as the only mechanism-specific treatment available for individuals at risk of rapid progression. Assessing the risk of rapid progression is discussed at greater length in a separate article in this special issue. This section will address use and prescription of tolvaptan in more detail and address other therapies that may be considered in the treatment of patients with ADPKD.
Collapse
Affiliation(s)
- William Ackley
- Department of Nephrology, University of Connecticut, Nephrology, Farmington, CT
| | - Neera K Dahl
- Section of Nephrology, Yale School of Medicine, New Haven, CT
| | - Meyeon Park
- Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA.
| |
Collapse
|
|
3
|
ADULT DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROTOTYPICAL DISEASE FOR PHARMANUTRITION INTERVENTIONS. PHARMANUTRITION 2022. [DOI: 10.1016/j.phanu.2022.100294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|